Search Result

Results for "

NEKs

" in MedChemExpress (MCE) Product Catalog:

By Targets:	NEKs (24) AAK1 (2) Amyloid-β (2) Apoptosis (13) Aurora Kinase (1) Autophagy (1) CaMK (1) CDK (3) Cyclin G-associated Kinase (GAK) (1) DYRK (1) Ferroptosis (1) LIM Kinase (LIMK) (2) NOD-like Receptor (NLR) (6) PROTACs (2) Pyroptosis (1) Ribosomal S6 Kinase (RSK) (1) Salt-inducible Kinase (SIK) (2) Ser/Thr Protease (1) Small Interfering RNA (siRNA) (11) ULK (1) Wee1 (1)
By Research Areas:	Cancer (21) Cardiovascular Disease (1) Inflammation/Immunology (7) Metabolic Disease (1) Neurological Disease (3)
Click Chemistry:	Alkynes (3)
Oligonucleotides:	Pre-designed siRNA Sets (11) siRNAs (11)

Inhibitors & Agonists

Natural
Products

Click Chemistry

Oligonucleotides

Targets Recommended: NEKs

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-153749

Nek2/Hec1-IN-2	NEKs	Cancer
Nek2/Hec1-IN-2 (Compound 14) is an inhibitor of *Nek2/Hec1. Nek*2/Hec1-IN-2 inhibits cancer cell proliferation with IC₅₀ >25 μM .

HY-122639

ZINC05007751 1 Publications Verification	NEKs	Cancer
ZINC05007751 is a potent NIMA-related kinase *NEK6* inhibitor with an IC₅₀ of 3.4 μM. ZINC05007751 shows antiproliferative activity against a panel of human cancer cell lines, and displays a synergistic effect with Cisplatin and Paclitaxel in a BRCA2 mutated ovarian cancer cell line. ZINC05007751 is very selective against NEK1 and NEK6 with no significant activity was observed against NEK2, NEK7, and NEK9 .

HY-100541

INH6	NEKs Apoptosis	Cancer
INH6 is a potent *Nek2/Hec1* inhibitor; inhibits the growth of HeLa cells with an IC₅₀ of 2.4 μM.

HY-117398

HCI-2184	NEKs	Cancer
HCI-2184 is a *Nek2* inhibitor with an IC₅₀ of 39.90 nM. HCI-2184 significantly increases the effectiveness of Bortezomib (HY-10227) in inhibiting proteasome activity .

HY-137046

Nek2-IN-4	NEKs	Cancer
Nek2-IN-4 is a potent *NEK2* inhibitor with an IC₅₀ value of 15 nM. Nek2-IN-4 inhibits cell proliferation. Nek2-IN-4 has the potential for the research of pancreatic cancer .

HY-168737

NEK7-IN-2	NOD-like Receptor (NLR) NEKs	Inflammation/Immunology
NEK7-IN-2 (compound 23) is a potent inhibitor of *NLRP3-NEK7* interaction. NEK7-IN-2 can enhance the thermal stability of NEK7 and regulatie NLRP3 inflammasome assembly. NEK7-IN-2 inhibits IL-1β releases .

HY-169933

NEK7-IN-1	NEKs	Inflammation/Immunology Cancer
NEK7-IN-1 (Compound I-15) is the inhibitor for NIMA-related kinase 7 *NEK7* with IC₅₀ <100 nM. NEK7-IN-1 inhibits the IL-1β release with IC₅₀ <50 nM .

HY-150046

Nek2-IN-6	NEKs	Cancer
Nek2-IN-6 (Compound 28e) is a potent never in mitosis (NIMA) related kinase 2 (Nek2) inhibitor .

HY-120330

Nek2-IN-5	NEKs	Cancer
Nek2-IN-5 (compound 6) is a potent and irreversible *Nek2* ((Never in mitosis gene a)-related kinase 2) inhibitior . Nek2-IN-5 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-RS09190

NEK1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
NEK1 Human Pre-designed siRNA Set A contains three designed siRNAs for NEK1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NEK1 Human Pre-designed siRNA Set A NEK1 Human Pre-designed siRNA Set A

HY-RS09191

NEK10 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
NEK10 Human Pre-designed siRNA Set A contains three designed siRNAs for NEK10 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NEK10 Human Pre-designed siRNA Set A NEK10 Human Pre-designed siRNA Set A

HY-RS09192

NEK11 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
NEK11 Human Pre-designed siRNA Set A contains three designed siRNAs for NEK11 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NEK11 Human Pre-designed siRNA Set A NEK11 Human Pre-designed siRNA Set A

HY-RS09193

NEK2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
NEK2 Human Pre-designed siRNA Set A contains three designed siRNAs for NEK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NEK2 Human Pre-designed siRNA Set A NEK2 Human Pre-designed siRNA Set A

HY-RS09194

NEK3 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
NEK3 Human Pre-designed siRNA Set A contains three designed siRNAs for NEK3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NEK3 Human Pre-designed siRNA Set A NEK3 Human Pre-designed siRNA Set A

HY-RS09195

NEK4 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
NEK4 Human Pre-designed siRNA Set A contains three designed siRNAs for NEK4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NEK4 Human Pre-designed siRNA Set A NEK4 Human Pre-designed siRNA Set A

HY-RS09196

NEK5 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
NEK5 Human Pre-designed siRNA Set A contains three designed siRNAs for NEK5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NEK5 Human Pre-designed siRNA Set A NEK5 Human Pre-designed siRNA Set A

HY-RS09197

NEK6 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
NEK6 Human Pre-designed siRNA Set A contains three designed siRNAs for NEK6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NEK6 Human Pre-designed siRNA Set A NEK6 Human Pre-designed siRNA Set A

HY-RS09198

NEK7 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
NEK7 Human Pre-designed siRNA Set A contains three designed siRNAs for NEK7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NEK7 Human Pre-designed siRNA Set A NEK7 Human Pre-designed siRNA Set A

HY-RS09199

NEK8 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
NEK8 Human Pre-designed siRNA Set A contains three designed siRNAs for NEK8 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NEK8 Human Pre-designed siRNA Set A NEK8 Human Pre-designed siRNA Set A

HY-RS09200

NEK9 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
NEK9 Human Pre-designed siRNA Set A contains three designed siRNAs for NEK9 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NEK9 Human Pre-designed siRNA Set A NEK9 Human Pre-designed siRNA Set A

HY-144425

BSc5367	NEKs	Inflammation/Immunology
BSc5367 is a potent *Nek1* inhibitor with an IC₅₀ of 11.5 nM. NIMA-related protein kinase Nek1 is crucially involved in cell cycle regulation, DNA repair and microtubule regulation and dysfunctions of Nek1 play key roles in amyotrophic lateral sclerosis (ALS), polycystic kidney disease (PKD) and several types of radiotherapy resistant cancer .

HY-16660

INH1 IBT13131	NEKs Apoptosis	Cancer
INH1 specifically disrupts the Hec1/Nek2 interaction via direct Hec1 binding. INH1 shows promising cancer inhibition activity both in vitro and in vivo .

HY-163756

NLRP3-IN-43	NOD-like Receptor (NLR)	Inflammation/Immunology
NLRP3-IN-43 (compound II-8) is a poteny inhibitor of NLRP3 inflammasome activation that binds to the LRR domain, and disrupts *NLRP3-NEK7* interaction .

HY-159520

Ofirnoflastum Ofirnoflast	NEKs	Inflammation/Immunology
Ofirnoflastum (Ofirnoflast) is a serine/ threonine-protein kinase Nek7 inhibitor, with anti inflammatory effect .

HY-103646

CK7	NEKs CDK	Others
CK7, a Cdk2/9 inhibitor, can be used for the synthesis of Nek1 inhibitor BSc5231 and BSc5367 .

HY-117154

INH154 1 Publications Verification	NEKs	Cancer
INH154 is a highly potent inhibitor for Nek2 and Hec1 binding (INH), with IC₅₀s of 200 nM and 120 nM for INH in Hela and MB468 cells.

HY-116423

JH295	NEKs	Cancer
JH295 is a potent, irreversible and selective NIMA-related kinase 2 (Nek2) inhibitor with an IC₅₀ of 770 nM. JH295 inhibits cellular *Nek2* via alkylation of Cys22. JH295 is inactive against the mitotic kinases, Cdk1, Aurora B or Plk1, and does not perturb bipolar spindle assembly or the spindle assembly checkpoint . JH295 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-116423A

JH295 hydrate	NEKs	Cancer
JH295 hydrate is a potent, irreversible and selective NIMA-related kinase 2 (Nek2) inhibitor with an IC₅₀ of 770 nM. JH295 hydrate inhibits cellular *Nek2* via alkylation of Cys22. JH295 hydrate is inactive against the mitotic kinases, Cdk1, Aurora B or Plk1, and does not perturb bipolar spindle assembly or the spindle assembly checkpoint . JH295 (hydrate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-156437

NBI-961	NEKs Ser/Thr Protease Apoptosis	Cancer
NBI-961 is a potent *NEK2* inhibitor that inhibits proteasomal degradation. NBI-961 induces G2/mitosis arrest and apoptosis in diffuse large B cell lymphoma (DLBCL) cells .

HY-N0373

Licochalcone B 5 Publications Verification	Amyloid-β Apoptosis NOD-like Receptor (NLR)	Neurological Disease
Licochalcone B is an extract from the root of Glycyrrhiza uralensis. Licochalcone B inhibits amyloid β (₄₂) self-aggregation (IC₅₀=2.16 μM) and disaggregate pre-formed Aβ₄₂ fibrils, reduce metal-induced Aβ₄₂ aggregation through chelating metal ionsLicochalcone B inhibits phosphorylation of NF-κB p65 in LPS signaling pathway. Licochalcone B inhibits growth and induces apoptosis of NSCLC cells. Licochalcone B specifically inhibits the NLRP3 inflammasome by disrupting NEK7‐NLRP3 interaction .

HY-101030

MBM-17	NEKs Apoptosis	Cancer
MBM-17 is a potent NIMA-related kinase 2 (Nek2) inhibitor with an IC₅₀ of 3 nM. It effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis. MBM-55 shows antitumor activities, and no obvious toxicity to mice .

HY-163358

SLC3037 1 Publications Verification	NOD-like Receptor (NLR) NEKs	Cardiovascular Disease Neurological Disease Inflammation/Immunology
SLC3037 is a NLRP3 inhibitor which blocks NLRP3 from binding to *NEK7* or oligomerization, inhibiting inflammasome caused by MSU and other inflammasome activators. SLC3037 can be used for research of gout, cardiovascular diseases, metabolic syndrome or neurodegenerative diseases .

HY-N0373R

Licochalcone B (Standard)	Amyloid-β Apoptosis NOD-like Receptor (NLR)	Neurological Disease
Licochalcone B (Standard) is the analytical standard of Licochalcone B. This product is intended for research and analytical applications. Licochalcone B is an extract from the root of Glycyrrhiza uralensis. Licochalcone B inhibits amyloid β (42) self-aggregation (IC50=2.16 μM) and disaggregate pre-formed Aβ42 fibrils, reduce metal-induced Aβ42 aggregation through chelating metal ionsLicochalcone B inhibits phosphorylation of NF-κB p65 in LPS signaling pathway. Licochalcone B inhibits growth and induces apoptosis of NSCLC cells. Licochalcone B specifically inhibits the NLRP3 inflammasome by disrupting NEK7‐NLRP3 interaction .

HY-101030A

MBM-17S	NEKs Apoptosis	Cancer
MBM-17S is a potent NIMA-related kinase 2 (Nek2) inhibitor, with an IC₅₀ of 3 nM. MBM-17S effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis. MBM-17S shows antitumor activities, and no obvious toxicity to mice .

HY-117884

(Rac)-CCT 250863	Apoptosis	Cancer
(Rac)-CCT 250863 (compound rac-21) is a selective and reversible NEK 2 inhibitor with an IC₅₀ of 0.073 µM. (Rac)-CCT 250863 shows good effects of inducing cell cycle arrest and also can antiproliferative in cells (Pomalidomide sensitive/resistant). (Rac)-CCT 250863 induces apoptosis when combines with Pomalidomide .

HY-120356

T-1101 TAI-95	Apoptosis NEKs	Cancer
T-1101 (TAI-95) is an orally active inhibitor for mitose regulating highly expressed oncoprotein 1 (Hec1). T-1101 blocks the interaction between Hec1 and *NEK2, exhibits cytotoxicity in human liver cancer cells with GI₅₀* of 15-70 nM. T-1101 induces apoptosis in Huh-7. T-1101 exhibits antitumor efficacy in mouse models .

HY-101029

MBM-55	NEKs Apoptosis	Cancer
MBM-55 is a potent NIMA-related kinase 2 (Nek2) inhibitor with an IC₅₀ of 1 nM. MBM-55 shows a 20-fold or greater selectivity in most kinases with the exception of RSK1 (IC₅₀=5.4 nM) and DYRK1a (IC₅₀=6.5 nM). MBM-55 effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis. MBM-55 shows antitumor activities, and no obvious toxicity to mice .

HY-120356A

T-1101 tosylate 1 Publications Verification TAI-95 tosylate	NEKs Apoptosis	Cancer
T-1101 tosylate (TAI-95 tosylate) is the tosylate salt form of T-1101 (HY-120356). T-1101 tosylate is an orally active inhibitor for mitose regulating highly expressed oncoprotein 1 (Hec1). T-1101 tosylate blocks the interaction between Hec1 and *NEK2, exhibits cytotoxicity in human liver cancer cells with GI₅₀* of 15-70 nM. T-1101 tosylate induces apoptosis in Huh-7. T-1101 tosylate exhibits antitumor efficacy in mouse models .

HY-101029A

MBM-55S	NEKs Ribosomal S6 Kinase (RSK) DYRK Apoptosis	Cancer
MBM-55S is a potent NIMA-related kinase 2 (Nek2) inhibitor with an IC₅₀ of 1 nM. MBM-55S shows a 20-fold or greater selectivity in most kinases with the exception of RSK1 (IC₅₀=5.4 nM) and DYRK1a (IC₅₀=6.5 nM). MBM-55S effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis. MBM-55S shows antitumor activities, and no obvious toxicity to mice .

HY-N3005

Britannin 1 Publications Verification	Apoptosis Autophagy NOD-like Receptor (NLR) Pyroptosis	Inflammation/Immunology Cancer
Britannin is an NLRP3 inhibitor with an IC₅₀ of 3.630 μM, exhibiting anti-inflammatory activity. Britannin inhibits the activation and assembly of the NLRP3 inflammasome by blocking the interaction between NLRP3 and *NEK7*. Additionally, Britannin demonstrates antitumor activity by inhibiting the proliferation of tumor cells through blocking the interaction between HIF-1α and Myc, thereby suppressing PD-L1 expression and enhancing cytotoxic T lymphocyte activity. Britannin can also induce apoptosis and autophagy in liver cancer cells by activating ROS-regulated AMPK. Britannin holds promise for research in the fields of anti-inflammatory and antitumor therapeutics .

HY-148062

RSS0680	PROTACs CDK AAK1 Cyclin G-associated Kinase (GAK) Salt-inducible Kinase (SIK) LIM Kinase (LIMK) Wee1	Others
RSS0680 (Example 22) is a bifunctional compound targeted protein degradation of kinases. RSS0680 degrades AAK1, CDK1, CDK16, CDK2, CDK4, CDK6, EIF2AK4, GAK, LATSl, LIMK2, MAPK6, MAPKAPK5, MARK2, MARK4, MKNK2, NEK9, RPS6KB1, SIK2, SNRK, STK17A, STK17B, STK35, and WEEl. RSS0680 can be used for research of disease or disorder mediated by aberrant kinase activity .(Pink: FLT3-IN-17 (HY-148070); Black: Linker (HY-W041970); Blue: E3 ligase Ligand (HY-112078))

HY-148063

DB0614	PROTACs AAK1 Aurora Kinase CaMK CDK Ferroptosis Salt-inducible Kinase (SIK) LIM Kinase (LIMK) ULK	Metabolic Disease
DB0614 is a PROTAC based on Cereblon ligand, which is a selective and potent targeted protein degrader of *NEK9* inhibitor. DB0614 can degrade ABL1, ABL2, BLK, CDK11B, CDK4, CSK, EPHA3, FER, GAK, LIMK1, MAP3K20, MAP4K1, MAP4K2, MAP4K3, MAP4K5, MAPK14, MAPK7, MAPK8, MAPK9, MAPKAPK2, MAPKAPK3, NLK, PDIK1L, PTK2B, RIPK1, RPS6KA1, RPS6KA3, SIK2, SIK3, STK35, TNK2 and ULK1. DB0614 can be used for research of disease or disorder mediated by aberrant kinase activity .(Blue: Thalidomide-4-OH (HY-103596), Black: linker, Pink: FLT3-IN-17 (HY-148070))

Cat. No.	Product Name	Category	Target	Chemical Structure